Previous evidence‐based guidelines have provided recommendations for prophylactic RBC matching beyond ABO and RhD in patients with SCD and thalassaemia aimed at reducing risks of alloimmunisation.5 This evidence concerns the gene ABO and Schnyder corneal dystrophy.